Biogen Inc. took a colossal risk in late 2019. It revived an Alzheimer’s disease drug it had left for dead earlier that year after it appeared to fail two large clinical trials.   
The company wasnt ready to take no for an answer. Biogen had poured years…

Click here to view the original article.